Simplex Trading
IMMX icon

Simplex Trading’s Immix Biopharma IMMX Stock Holding History

Simplex Trading’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
+1,300
New +$12.1K ﹤0.01% 7452
2026
Q1 		– Sell
-7,800
Closed -$40.8K – 9566
2025
Q4 		$40.8K Buy
+7,800
New +$32.1K ﹤0.01% 5846

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading's IMMX Position: Q2 2026 in Review

Simplex Trading reduced its Immix Biopharma (IMMX) stake by 10% in Q2 2026, selling an estimated $4.12K and leaving 3,811 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6528.

Simplex Trading first reported a position in IMMX in Q1 2024 and has held it in 5 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Simplex Trading held 3,811 shares of Immix Biopharma worth $39.3K as of Q2 2026.
  • Simplex Trading sold 444 Immix Biopharma shares in Q2 2026, an estimated $4.12K.
  • Immix Biopharma made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6528 holding.
  • Simplex Trading first reported a position in Immix Biopharma in Q1 2024 and has held it in 5 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.